B. Riley raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $24 from $20 and keeps a Neutral rating on the shares following the ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) had its target price boosted by equities researchers at B. Riley from $20.00 to $24.00 in a note issued to investors on Wednesday ...

Equities research analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Tuesday, March 4th. B. Riley analyst K. Patel expects that ...

March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq ... which developed the FDA-approved CAR T-cell therapy ...

Explore Rigel Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RIGL. Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $55 from $49 and keeps a Buy rating on the ...

Raul Rodriguez; President, Chief Executive Officer, Director; Rigel Pharmaceuticals Inc David Santos; Executive Vice President, Chief Commercial Officer; Rigel Pharmaceuticals Inc Lisa Rojkjaer; ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported fourth-quarter earnings of $14.3 million. On a per-share basis ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

He holds a B.S. from Yale College and an M.D. from Harvard Medical School. His academic accolades include a chief residency and a Howard Hughes postdoctoral fellowship at UCSF. Rigel’s president ...

Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET. Company Participants. Ray Furey - Executive Vice President, General Counsel & ...